Showing results (1051-1060 of 1,139) with videos related to

Sort By:
Pageof 114
JOR Spine|August 14, 2025
Patient-Reported Outcomes Among an Observational Cohort of Individuals With Chronic Low Back PainCarol M Greco, Nathan E Dodds, Amanda M Acevedo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 5, 2020
Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 studyE Van Cutsem, I Danielewicz, M P Saunders, et al.
Schmerz (Berlin, Germany)|February 21, 2024
[Evidence-based interventions to treat chronic low back pain: treatment selection for a personalized medicine approach : German version]Matthew C Mauck, Aileen F Aylward, Chloe E Barton, et al.
Pain Reports|October 7, 2022
Evidence-based interventions to treat chronic low back pain: treatment selection for a personalized medicine approachMatthew C Mauck, Aileen F Aylward, Chloe E Barton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2013
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivityElizabeth Poplin, Harpreet Wasan, Lindsey Rolfe, et al.
BMC Cancer|June 2, 2016
ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumoursEva Segelov, Paul Waring, Jayesh Desai, et al.
The Lancet. Oncology|June 7, 2011
Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialRichard A Adams, Angela M Meade, Matthew T Seymour, et al.
Pain Medicine (Malden, Mass.)|February 1, 2023
The Back Pain Consortium (BACPAC) Research Program Data Harmonization: Rationale for Data Elements and StandardsAnna Batorsky, Anton E Bowden, Jessa Darwin, et al.
The Lancet. Oncology|April 2, 2021
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trialAngela Lamarca, Daniel H Palmer, Harpreet Singh Wasan, et al.
Pain|July 13, 2018
Evaluation of composite responder outcomes of pain intensity and physical function in neuropathic pain clinical trials: an ACTTION individual patient data analysisKushang V Patel, Robert Allen, Laurie Burke, et al.
Pageof 114